Biogen pressed against the wall as more stakeholders side against Aduhelm; Prime time for CRISPR 3.0?; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
As the Endpoints team grows, we are finding more time to do interviews under embargoes and pursue more in-depth features — personally two of my favorite parts of this job. Got news lined up in the near future? You can always reach us at firstname.lastname@example.org.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.